BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 18310543)

  • 21. [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study.
    Buchmann I; Neumaier B; Schreckenberger M; Reske S
    Cancer Biother Radiopharm; 2004 Aug; 19(4):436-42. PubMed ID: 15453958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [18F] FDG PET in gastric non-Hodgkin's lymphoma.
    Rodriguez M; Ahlström H; Sundín A; Rehn S; Sundström C; Hagberg H; Glimelius B
    Acta Oncol; 1997; 36(6):577-84. PubMed ID: 9408147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
    Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma.
    Chang CC; Cho SF; Chen YW; Tu HP; Lin CY; Chang CS
    Clin Nucl Med; 2012 Aug; 37(8):e189-95. PubMed ID: 22785526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
    Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
    Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
    Ambrosini V; Rubello D; Castellucci P; Nanni C; Farsad M; Zinzani P; Alavi A; Tehranipour N; Al-Nahhas A; Fanti S
    Nucl Med Rev Cent East Eur; 2006; 9(1):37-40. PubMed ID: 16791802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
    Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
    Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
    Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD
    J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse skeletal muscle F-18 fluorodeoxyglucose uptake in advanced primary muscle non-Hodgkin's lymphoma.
    Broski SM; Bou-Assaly W; Gross MD; Fig LM
    Clin Nucl Med; 2009 Apr; 34(4):251-3. PubMed ID: 19300063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multimodality imaging of direct ureteric involvement in non-Hodgkin's lymphoma using PET/CT, CT urography and antegrade CT pyelography.
    Ghersin E; Keidar Z; Eldad DJ; Bar-Shalom R; Fischer D; Halachmi S
    Br J Radiol; 2007 Nov; 80(959):e283-6. PubMed ID: 17989329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [18F-FDG uptake of lymphoma lesions of various histological subtypes].
    Ma LF; Fan W
    Ai Zheng; 2009 Apr; 28(4):425-30. PubMed ID: 19622306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
    Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
    Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.
    Brepoels L; Stroobants S; De Wever W; Spaepen K; Vandenberghe P; Thomas J; Uyttebroeck A; Mortelmans L; De Wolf-Peeters C; Verhoef G
    Leuk Lymphoma; 2007 Aug; 48(8):1522-30. PubMed ID: 17701583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
    Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
    Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.